ReviewAnnals of general psychiatry2026
Mechanisms and clinical potential of combined tDCS and virtual reality in psychiatric disorders: a systematic review.
Review in Annals of general psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTranscranial direct current stimulation (tDCS) and virtual reality (VR) have emerged as promising non-invasive interventions in treating psychiatric disorders. Despite their individual efficacy in improving symptoms of various psychiatric conditions, the understanding of the combined use of tDCS and VR is limited. This review aims to evaluate the clinical effects and mechanisms of combined tDCS and VR in treating psychiatric disorders.
methodsWe conducted a PRISMA 2020-compliant systematic review, searching major databases (PubMed, Web of Science, Scopus, PsycINFO, ScienceDirect, Cochrane Library, Google Scholar, medRxiv and ClinicalTrials.gov) for studies from January 2000 to July 2025 that evaluated combined tDCS-VR in psychiatric populations. Eligible clinical trials were screened, with tDCS/VR parameters and clinical outcomes extracted, and randomized controlled trials appraised using the Cochrane Risk of Bias 2 tool.
resultsFourteen studies met inclusion criteria: seven reviews and seven empirical trials (five randomized controlled trials, two pilot/feasibility studies) using mainly 1-2 mA prefrontal tDCS paired with disorder-congruent VR. In post-traumatic stress disorder (PTSD) and specific phobias showed short-term symptom reductions, with some PTSD benefits maintained up to 12 months. Evidence for social anxiety and mild cognitive impairment-related depression was limited to single small RCTs with transient or inconsistent improvements. Overall confidence in the evidence is limited by small sample sizes, variable protocols, and risk‑of‑bias concerns.
conclusionAlthough seven small, heterogeneous studies indicate that combined tDCS-VR is feasible and shows preliminary therapeutic promise-most consistently in PTSD and, to a lesser extent, in specific phobias-the overall evidence base remains limited. Mechanistic findings suggesting modulation of medial and ventromedial prefrontal-amygdala circuits are still exploratory. Given substantial methodological heterogeneity, small sample sizes, and risk of bias, tDCS-VR should be regarded as experimental. The larger, well‑designed, disorder‑tailored randomized controlled trials using standardized stimulation/VR protocols, mechanistic outcome measures, and efforts to identify predictors of response are required before routine clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.